FDA Clears 20 Zyn Pouches for Lower-Risk Marketing as Trump Loosens Nicotine Rules
Updated
Updated · CNBC · Jun 30
FDA Clears 20 Zyn Pouches for Lower-Risk Marketing as Trump Loosens Nicotine Rules
3 articles · Updated · CNBC · Jun 30
Summary
Twenty Zyn nicotine pouch products can now be marketed as less harmful than cigarettes, letting Philip Morris claim switching lowers risks of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.
Tuesday’s order goes beyond the FDA’s January 2025 authorization to sell the same 20 products by granting a modified-risk designation—the first for nicotine pouches.
Zyn contains nicotine but no tobacco, and the FDA said the decision does not mean it is safe; youth should not use tobacco products and nonusers should not start.
The clearance gives Philip Morris a valuable health-related pitch as U.S. cigarette sales decline and tobacco groups push smoke-free products under a more industry-friendly Trump administration.
With youth use doubling, can the FDA's 'less harmful' label for Zyn coexist with preventing a new addiction crisis?
As the U.S. endorses Zyn, why have multiple European nations banned these same pouches over youth safety concerns?
FDA Authorizes ZYN as First Modified Risk Nicotine Pouch: Scientific Rationale, Public Health Impact, and Regulatory Implications (2026)
Overview
On June 30, 2026, the FDA made a landmark decision by authorizing ZYN nicotine pouches as Modified Risk Tobacco Products, marking the first time such a product received this status. This followed an extensive scientific review that examined ZYN’s health risks, how well consumers understand the reduced-risk claims, youth usage data, and the overall impact on public health. As a result, Swedish Match USA Inc. can market ZYN with specific reduced-risk claims, but must meet strict conditions and ongoing oversight to ensure these products continue to benefit public health and do not increase youth use.